With $1B Novo deal and diabetes ambitions undimmed, Lexicon is in ‘good shape to go crazy’

Three weeks into taking on the role of Lexicon Pharmaceuticals CEO back in 2024, Michael Exton told Fierce the company close its commercial operations.